


Hepatocarcinoma: present and future directives




Tim F. Greten, M.D.
 Department of Gastroenterology, Hepatology und Endocrinology
 Medical School Hannover
 greten.tim@mh-hannover.de

HCC - a different tumor


- occurs in a damaged organ
- diagnosis without histology possible
- different tumor staging system
- transplantation as a curative therapy option
- local ablative therapies
- no cytotoxic chemotherapy established
- RECIST criteria have no value after locoregional therapy to evaluate tumor response




Strategies to prevent HCC recurrence after resection





Meta-analysis of four RCTs comparing 3-year OS between RFTA versus PEI for unresectable HCC



TACE for the treatment of HCC



Camma et al. Radiology (2002) 224:47-54
 Llovet et al. Hepatology (2003) 37:429-42
 Marelli et al. Cardiovasc Intervent Radiol (2007) 30:6-25



Phase III SHARP Trial

Response assessment (RECIST; Independent review)
Time to symptom progression (FSH18-TSP)*

	Sorafenib (n=299)	Placebo (n=303)
Overall response		
Complete response (CR)	0	0
Partial response (PR)	7 (2.3%)	2 (0.7%)
Stable disease (SD)	211 (71%)	204 (67%)
Progressive disease	54 (18%)	73 (24%)
Progression-free rate at 4 mo	62%	42%
Duration of treatment (median, weeks)	23	19

*FSH18-TSP: No significant differences between treatment groups ($P=0.77$)

Safety events

Adverse event	Sorafenib (N=297)			Placebo (N=302)		
	Any	3	4	Any	3	4
Overall incidence	80			52		
Constitutional incidence						
Fatigue	22	3	1	16	3	<1
Weight	9	2	0	1	0	0
Dermatology/skin						
Alpecia	14	0	0	2	0	0
Dry skin	8	0	0	4	0	0
Hand-foot skin reaction	21	8	0	3	<1	0
Pruritus	8	0	0	7	<1	0
Rash/desquamation	16	1	0	11	0	0
Gastrointestinal						
Anorexia	14	<1	0	3	1	0
Diarrhea	39	8	0	11	2	0
Nausea	11	<1	0	8	1	0
Vomiting	5	1	0	3	1	0
Hepatobiliary						
Liver dysfunction	<1	<1	<1	0	0	0
Pain						
Pain, abdomen	8	2	2	3	1	0
Bleeding	7	1	2	4	1	<1

Llovet et al. J Clin Oncol (2007)25(18S):962s

SHARP - subgroup analysis

subgroup	TTP	OS	Ref.
HCV (n=178)	7.6 vs. 2.8	14.0 vs. 7.9	Bolondi, ASCO-GI
C2-tox (n=79)	5.5 vs. 3.9	10.3 vs. 7.99	Craxi, ASCO
ECOG 0 (n=325)	5.5 vs. 2.9	13.3 vs. 8.8	Raoul, ASCO
ECOG 1-2 (n=277)	5.3 vs. 2.8	8.9 vs. 5.6	
ALT/AST			
norm. (n=292)	5.5 vs. 3.3	13 vs. 9	Greten, ASCO-GI
<1.8 (n=160)	5.5 vs. 2.8	11 vs. 8	
1.8 - 3 (n=146)	5.5 vs. 2.7	8 vs. 5.5	
MVI or Metast. (n=421)	4.1 vs. 2.7	8.9 vs. 6.7	Sherman, ASCO
No MVI or Metast. (n=181)	9.6 vs. 4.3	14.5 vs. 4.2	
Pretreatment			
Curative (n=158)	5.5 vs. 2.7	11.9 vs. 8.8	Galle, EASL
TACE (n=176)	5.8 vs. 4.0	11.9 vs. 9.9	

